Immunovant (IMVT) Receivables (2021 - 2026)

Immunovant's Receivables history runs 6 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• Quarterly Receivables fell 45.63% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 45.63% YoY) and the FY2026 annual result came in at $1.1 million, down 45.63% from the prior year.
• Receivables was $1.1 million for Q1 2026 at Immunovant, down from $1.6 million in the prior quarter.
• Across five years, Receivables topped out at $13.2 million in Q2 2022 and bottomed at $700000.0 in Q1 2023.
• A 5-year average of $3.2 million and a median of $1.9 million in 2025 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables surged 1951.85% — and 2023, when it plunged 94.28%.
• Immunovant's Receivables stood at $704000.0 in 2022, then soared by 46.16% to $1.0 million in 2023, then jumped by 116.13% to $2.2 million in 2024, then retreated by 26.12% to $1.6 million in 2025, then plunged by 31.04% to $1.1 million in 2026.
• Business Quant data shows IMVT's Receivables at $1.1 million in Q1 2026, $1.6 million in Q4 2025, and $2.0 million in Q3 2025.